• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Medicines Patent Pool Signs New Licence Agreements

26/06/2013 by Intellectual Property Watch 1 Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

By Brittany Ngo for Intellectual Property Watch

The Medicines Patent Pool, Shilpa Medicare, and Gilead Sciences have signed an agreement to increase access to HIV treatment medicines. The agreement will allow Shilpa Medicare to manufacture “five key HIV medicines for sale in 100-112 countries,” and the goal is to cover “a majority of people living with HIV.”

In a press release, the Medicines Patent Pool (MPP) said Indian company Shilpa Medicare joins the group of five other generic manufacturers who are currently signed up to produce HIV medicines licensed to the Pool by Gilead Sciences in July 2011. Doing so, the Pool said, “will help ensure the supply of key HIV medicines will grow to meet rising demands for HIV treatment. The medicines covered in this agreement [pdf] are: tenofovir, emtricitabine, cobicistat, elvitegravir and a combination of the four known as ‘the Quad’.”

The exact number of countries in which the drugs can be sold depends on the drug in question. Under the agreement, Shilpa will be able to sell tenofovir and emtricitabine in 112 countries, cobicistat in 103 countries, and elvitegavir and “the Quad” in 100 countries. Some larger markets like India and South Africa are covered for all the drugs, while others such as Brazil and China are left out of the agreement.

Earlier this week, the MPP also signed an agreement with Indian generics producer Aurobindo Pharma Limited, and ViiV Healthcare, a joint venture of GlaxoSmithKline, Pfizer, and Shiongi.

The licence agreement allows Aurobindo to produce HIV treatment drugs for children. Medicines containing abacavir, the WHO recommended treatment for paediatric HIV, can now be sold by Aurobindo “in the 118 countries where 98.7% of children living with HIV reside.” Brazil and China are also not included in the 118 countries covered by the agreement.

The Medicines Patent Pool is a Geneva-based non-profit organisation founded in 2010 by the WHO-based UNITAID, and works to lower prices on HIV medicines and encourage development of new ones.

Brittany Ngo is currently completing her Master’s in Health Policy and Global Health at the Yale School of Public Health and previously obtained a Bachelor’s of Arts in Economics from Georgetown University. Through her studies she has developed an interest in health-related intellectual property issues. She is a summer intern at Intellectual Property Watch.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"Medicines Patent Pool Signs New Licence Agreements" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, English, Health & IP, Patents/Designs/Trade Secrets, Technical Cooperation/ Technology Transfer, WHO

Trackbacks

  1. Medicines Patent Pool, Roche Strike HIV-Related Medicine Pricing Agreement | Intellectual Property Watch says:
    05/08/2013 at 7:43 am

    […] previous agreements negotiated to licence particular drugs (IPW, WHO, 26 June 2013) (IPW, WHO, 11 October 2011), the agreement with Roche is a pricing agreement […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2022 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.